Conference Coverage

Biogen’s aducanumab stumbles on cognitive endpoints at 6 mg/kg dose

Publish date: July 23, 2015

 

FROM AAIC 2015

References

msullivan@frontlinemedcom.com

On Twitter @Alz_Gal

Pages

Recommended Reading

Prevalence of amyloid pathology differs across dementia type and age
MDedge Psychiatry
PSYCHIATRY UPDATE 2015
MDedge Psychiatry
Cortical volume linked to IQ changes in schizophrenia
MDedge Psychiatry
Provide your patients with a DEFENSE against age-related cognitive decline
MDedge Psychiatry
Consider telehealth technology to perform reliable and valid cognitive screening
MDedge Psychiatry
Mixed pathologies are very common in black Alzheimer’s patients
MDedge Psychiatry
AAIC: Sedentary early adulthood may mean worse cognitive functioning later
MDedge Psychiatry
VIDEO: Dementia risk doubled in type 1 diabetes patients
MDedge Psychiatry
VIDEO: Investigating the role of plasmalogens in Alzheimer’s disease
MDedge Psychiatry
VIDEO: Postoperative cognitive decline hits women hardest
MDedge Psychiatry